A new UAB study reports on a potential new treatment for frontotemporal dementia, the second most common type after Alzheimer’s disease.
Research into rare diseases gets a funding boost from the NIH: UAB researchers studying Rett syndrome and tuberous sclerosis among those involved in the national effort.
Philanthropic support has enabled the UAB Department of Neurology to make huge strides in knowledge of diseases such as Parkinson’s.
The first patient in the Southeast to get the RNS responsive neurostimulation seizure-control device implanted in the brain reports dramatic results at UAB.
The eye is a window to the brain; scientists discover early signs of dementia in changes to neurons in the eye’s retina.
UAB is the first medical center in the Southeast to implant a new type of electrical stimulator to control seizures in patients with epilepsy.
The University of Alabama Board of Trustees approved the creation of the Personalized Medicine Institute, the Institute for Informatics and the UAB-HudsonAlpha Center for Genomic Medicine.
Neurologist David Geldmacher, M.D., is launching a new clinical effort to prepare a personalized dementia risk assessment for people concerned about their risk for developing memory problems as they age.
Anthony Nicholas, M.D., associate professor in the Department of Neurology, is a co-editor of the first textbook on the subject of protein deimination in human health and disease.
New drugs to slow or even prevent Parkinson’s could be in human studies as early as 2015.